Scout Investments, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Scout Investments, Inc.

$3.78 Billion
Q1 2024

A detailed history of Scout Investments, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Scout Investments, Inc. holds 265,525 shares of SUPN stock, worth $7.3 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

265,525

Previous 282,400 5.98%

Holding current value

$7.3 Million

Previous $8.17 Million 10.83%

% of portfolio

0.24%

Previous 0.22%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$27.11 - $35.17 $457,481 - $593,493	-16,875 Reduced 5.98%	265,525 $9.06 Million
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $100,626 - $131,452	-4,429 Reduced 1.54%	282,400 $8.17 Million
Q3 2023 Nov 09, 2023	SELL	$27.57 - $32.91 $229,630 - $274,107	-8,329 Reduced 2.82%	286,829 $7.91 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $262,789 - $340,281	-8,786 Reduced 2.89%	295,158 $8.87 Million
Q1 2023 May 11, 2023	SELL	$34.93 - $42.03 $124,280 - $149,542	-3,558 Reduced 1.16%	303,944 $11 Million

Q4 2022 Jan 23, 2023	SELL	$31.09 - $37.88 $159,025 - $193,756	-5,115 Reduced 1.64%	307,502 $0
Q3 2022 Oct 18, 2022	SELL	$28.79 - $35.41 $253,812 - $312,174	-8,816 Reduced 2.74%	312,617 $10.6 Million
Q2 2022 Jul 15, 2022	SELL	$25.33 - $34.25 $692,294 - $936,086	-27,331 Reduced 7.84%	321,433 $9.3 Million
Q1 2022 Apr 14, 2022	SELL	$28.51 - $32.9 $283,760 - $327,453	-9,953 Reduced 2.77%	348,764 $11.3 Million
Q4 2021 Jan 14, 2022	SELL	$26.37 - $34.22 $213,755 - $277,387	-8,106 Reduced 2.21%	358,717 $10.5 Million
Q3 2021 Oct 13, 2021	SELL	$23.54 - $31.39 $296,910 - $395,922	-12,613 Reduced 3.32%	366,823 $9.78 Million
Q2 2021 Jul 23, 2021	SELL	$26.72 - $33.19 $14,215 - $17,657	-532 Reduced 0.14%	379,436 $11.7 Million
Q1 2021 Apr 09, 2021	BUY	$24.15 - $31.45 $2.2 Million - $2.86 Million	90,940 Added 31.46%	379,968 $9.95 Million
Q4 2020 Jan 12, 2021	BUY	$17.7 - $25.81 $398,037 - $580,415	22,488 Added 8.44%	289,028 $7.27 Million
Q3 2020 Oct 13, 2020	BUY	$20.2 - $25.05 $755,964 - $937,471	37,424 Added 16.33%	266,540 $5.56 Million
Q2 2020 Jul 14, 2020	SELL	$17.09 - $24.89 $28,181 - $41,043	-1,649 Reduced 0.71%	229,116 $5.44 Million
Q1 2020 Apr 16, 2020	SELL	$14.45 - $24.69 $183,370 - $313,316	-12,690 Reduced 5.21%	230,765 $4.15 Million
Q4 2019 Jan 08, 2020	SELL	$19.93 - $29.13 $5.37 Million - $7.84 Million	-269,280 Reduced 52.52%	243,455 $5.78 Million
Q3 2019 Oct 08, 2019	SELL	$25.47 - $33.37 $3.73 Million - $4.89 Million	-146,546 Reduced 22.23%	512,735 $14.1 Million
Q2 2019 Jul 10, 2019	SELL	$29.96 - $38.87 $3.24 Million - $4.21 Million	-108,223 Reduced 14.1%	659,281 $21.8 Million
Q1 2019 Apr 12, 2019	SELL	$32.77 - $41.99 $2.38 Million - $3.04 Million	-72,513 Reduced 8.63%	767,504 $26.9 Million
Q4 2018 Jan 11, 2019	BUY	$30.84 - $49.51 $10.1 Million - $16.2 Million	327,870 Added 64.02%	840,017 $27.9 Million
Q3 2018 Oct 15, 2018	SELL	$42.7 - $56.55 $3.54 Million - $4.69 Million	-82,949 Reduced 13.94%	512,147 $25.8 Million
Q2 2018 Jul 16, 2018	BUY	$44.1 - $59.85 $18.4 Million - $24.9 Million	416,696 Added 233.57%	595,096 $35.6 Million
Q1 2018 May 09, 2018	SELL	$37.15 - $46.9 $15.5 Million - $19.5 Million	-416,462 Reduced 70.01%	178,400 $8.17 Million
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $1.05 Million - $1.23 Million	28,962 Added 5.12%	594,862 $23.7 Million
Q3 2017 Nov 03, 2017	BUY	$36.75 - $49.65 $14.7 Million - $19.8 Million	399,225 Added 239.52%	565,900 $22.6 Million
Q2 2017 Aug 08, 2017	BUY	N/A	166,675	166,675 $7.18 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.47B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Scout Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scout Investments, Inc. with notifications on news.

Account

Scout Investments, Inc. Supernus Pharmaceuticals, Inc. Transaction History